| abstract |
The present invention relates to an aqueous formulation comprising a compound having a concentration of at least about 20 mg/ml and a GM-CSF, a strain modifier, a buffer, and one or more of the following: a surfactant, an amino acid, an antioxidant And/or a chelating agent, wherein the composition is stable. In view of long-term storage, the ingredients of the formulation are preferably provided to provide stability to the compound which neutralizes GM-CSF. In a preferred aspect, the formulation is for use in therapy, preferably for the treatment of inflammatory and autoimmune disorders, preferably allergic and psoriasis disorders, as well as arthritic and asthmatic disorders. Additionally, a kit comprising the formulation of the invention is provided. |